-
08:47:45 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

PFE - Pfizer Inc.

09/22/21 9:44 PM
NYSE, Nasdaq : PFE, BNTX
covid-19
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine Booster
Pfizer Inc. and BioNTech SE today announced that the U.S. Food and Drug Administration has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 years of age at high risk of severe COVID-19, and individuals 18 through 64 years of age whose...
RHEA-AI
neutral
09/20/21 10:00 AM
NYSE : PFE
conferences
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the Cantor Global Healthcare Conference on Monday, September 27, 2021 at 12:10 p.m. Eastern Daylight Time. About Pfizer: Breakthroughs That Change Patients’ Lives. At Pfizer, we apply science and our global resources to bring...
RHEA-AI
neutral
09/20/21 6:45 AM
NYSE, Nasdaq : PFE, BNTX
covid-19
Pfizer and BioNTech Announce Positive Topline Results From Pivotal Trial of COVID-19 Vaccine in Children 5 to 11 Years
Results are the first from a pivotal trial of any COVID-19 vaccine in children under 12 years of age In participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responses Companies plan to submit these data to the FDA, EMA and other regulatory agencies around the world as soon as possible Results in children...
RHEA-AI
neutral
09/17/21 7:21 PM
NYSE, Nasdaq : PFE, BNTX
FDA Advisory Committee Votes Unanimously in Favor Of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-risk Populations
Committee reviewed clinical data showing a booster dose of COMIRNATY ® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants Reactogenicity profile within seven days of the booster dose was typically mild to moderate, with frequency of reactions similar to or lower than after the primary vaccination series...
RHEA-AI
neutral
09/09/21 6:45 AM
NYSE : PFE
UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
Pfizer Inc. today announced that the UK Medicines and Healthcare products Regulatory Agency has granted Great Britain marketing authorization for CIBINQO ®, an oral, once-daily, Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and over, who are candidates for systemic therapy.
RHEA-AI
neutral
09/07/21 10:00 AM
NYSE : PFE
conferences
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences
Pfizer Inc. invites investors and the general public to listen to two webcasts of discussions with Pfizer executives at two upcoming healthcare conferences. About Pfizer: Breakthroughs That Change Patients’ Lives. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
RHEA-AI
neutral
09/02/21 6:45 AM
NYSE : PFE
clinical trial
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
Pfizer Inc. today announced the initiation of RENOIR, a Phase 3 clinical trial evaluating the efficacy, immunogenicity, and safety of a single dose of its respiratory syncytial virus bivalent prefusion F subunit investigational vaccine candidate in adults ages 60 years or older. There is an important unmet medical need for an effective vaccine that can help...
RHEA-AI
negative